TABLE 2:
Primary and secondary outcomes at the end of the follow-up period.
| Outcomes | Normal (N= 414) | Overweight (N= 1,189) | Obese (N= 3,231) |
|---|---|---|---|
| NAFLD with cirrhosis patients | 6 | 36 | 124 |
| Compensated patients | 1 | 15 | 43 |
| Decompensated patients | 5 | 21 | 81 |
| Ascites events | 4 | 18 | 69 |
| Bleeding Varices events | 1 | 5 | 12 |
| Hepatic Encephalopathy events | 2 | 4 | 45 |
| Jaundice events | 3 | 9 | 42 |
| Any CV event * | 120 | 373 | 988 |
| Any Cancer event | 68 | 206 | 446 |
| Colon Cancer | 12 | 37 | 58 |
| Liver Cancer | 3 | 6 | 16 |
| Pancreatic Cancer | 7 | 8 | 27 |
| Stomach Cancer | 2 | 5 | 10 |
| Esophageal Cancer | 1 | 4 | 4 |
| Breast Cancer | 30 | 54 | 160 |
| Prostate Cancer | 10 | 65 | 84 |
| Uterine Cancer | 5 | 13 | 72 |
| Ovarian Cancer | 4 | 8 | 23 |
| Lung Cancer | 12 | 28 | 51 |
| Death | 74 | 148 | 347 |
*
Cardiovascular (CV) events: myocardial infarction, stroke, angina, atrial fibrillation, or cardiac arrest.